Navigation Links
Study identifies potential new strategy to improve odds of corneal transplant acceptance

DALLAS Dec. 30, 2013 For the estimated 10 percent of patients whose bodies reject a corneal transplant, the odds of a second transplant succeeding are poor. All that could change, however, based on a UT Southwestern Medical Center study that has found a way to boost the corneal transplant acceptance rate.

In the study, researchers found that corneal transplants in mice were accepted 90 percent of the time when the action of an immune system molecule called interferon-gamma (IFN-γ) was blocked and when the mice shared the same major histocompatibility complex (MHC) genotype as the donor cornea. MHC matching is not typically done with human corneal transplants because of a high acceptance rate.

"Our findings indicate that neither MHC matching alone nor administration of anti-IFN-γ antibody alone enhances graft survival. However, we found that when MHC matching is combined with anti-IFN-γ therapy, long-term corneal transplant survival is almost guaranteed," said Dr. Jerry Niederkorn, Professor of Ophthalmology and Microbiology at UT Southwestern and senior author of the study.

The study findings, reported in the December issue of the American Journal of Transplantation, suggest an option to improve the odds of a subsequent corneal transplant's success for those patients whose first transplant was rejected.

More than 40,000 corneal transplants are performed annually in the United States, making this surgical procedure one of the most common and successful in transplantation. But out of that total, about 4,000 fail, with the recipient's body rejecting the corneal graft and requiring a second operation.

A surprising finding of the study was learning that IFN-γ can act both as an immune system suppressor or activator, depending on the context of the histocompatibility antigens perceived by the immune system, Dr. Niederkorn said. Earlier studies indicated that this molecule only activated immune system rejection of transplants and that disabling IFN-γ would improve the acceptance rate. But that was not necessarily the case; researchers found that when there was no MHC matching between the mice and the transplants, and IFN-γ was disabled, the transplant rejection rate was 100 percent.

"Under those conditions, IFN-γ was needed to maintain the T regulatory cells, which suppress the immune response," Dr. Niederkorn said.

Rather than recommend transplant matching and inactivation of IFN-γ for all first-time corneal transplant recipients, Dr. Niederkorn said this strategy would make most sense for those who have already rejected a cornea, or for those individuals believed to be at risk for a corneal transplant rejection. But before a clinical trial can be launched to verify the results obtained in mice, further study is needed.

"We are working to develop an IFN-γ antibody in eye-drop form," Dr. Niederkorn said. "Then we need to test whether this antibody will work in animal models."

Lead author of the study was Dr. Khrishen Cunnusamy, a former postdoctoral researcher in Dr. Niederkorn's lab and current UT Southwestern medical student.


Contact: Debbie Bolles
UT Southwestern Medical Center

Related medicine news :

1. New study: High mortality in Central Southern states most likely due to smoking
2. Contract Research Organization WCCT Global Announces Milestone for Clinical Study Completion
3. As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Finding that Acetaminophen Combined With Alcohol May Increase Risk for Kidney Damage
4. Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Notes Publication of New Study Questioning Cost, Benefits of Robotic Surgery
5. PDL-1 antibody could help immune system fight off influenza viral infection, study suggests
6. Study shows value of calcium scan in predicting heart attack, stroke among those considered at risk
7. Embargoed study: New quality, payment initiative positively impacts pediatric care
8. PM2.5 Monitor Industry in Global and China Regions 2013 Analysis in a New Study at
9. Austin Doctor Participates in Flu Vaccine Research Study in an Effort to Find More Effective Vaccines.
10. UV Technologies, LLC, Makers of UV-Aid® Release Results of Study Showing Photo-Oxidation Technology Highly Effective in Preventing Colds, Flu, and Ear Infections
11. Agein Corporation, a Leading Anti-Aging Company, Responds to Study Showing Personal Care Products a Possible Source of Harmful Parabens for Babies
Post Your Comments:
Related Image:
Study identifies potential new strategy to improve odds of corneal transplant acceptance
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center ... and is the only hospital in the region providing what is known as ... transcatheter pacing patients were revealed recently at a medical conference and published in ...
(Date:12/1/2015)... MD (PRWEB) , ... December 01, 2015 , ... ... salmon identification tests to continue the expansion of the company’s growing product line ... – for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... for Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or ... anticipated results, once a deal is signed. This quick-read guidance suggests that ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... During the recent 2015 Transcatheter Cardiovascular ... CA , Medinol Ltd. continued to introduce ... a satellite symposium, "The BioNIR eDES: The Role ... a renowned physician panel discussed the key attributes ... Stent System and the Medinol eDES Coronary Stent ...
(Date:12/1/2015)... YORK , Dec. 1, 2015 Relmada Therapeutics, ... the treatment of chronic pain, announced today that the company ... will be held December 1-3 at the Luxe Sunset Boulevard ... Sergio Traversa , CEO of Relmada Therapeutics, will present on ... Eastern Time). . Please register at least ...
(Date:12/1/2015)... Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), a ... of therapies for cardiovascular conditions via the inhalation route, ... in Australia . InCarda is planning ... Australia in the first half of ... medical centers in Adelaide and ...
Breaking Medicine Technology: